ASND
Ascendis Pharma A/S · Healthcare · Biotechnology
Señales de momentum (gestores comparables):
amplitud de titulares +9.1% ·
flujo de acciones -11.2% ·
nuevas posiciones netas +8.3%
— fórmula
Fragmentación de la titularidad — más titulares, participación agregada menor
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q2 2026 | 106 | +15 | 28.56M | $7.62B | +25 | −10 |
| Q1 2026 | 92 | -6 | 28.38M | $6.48B | +8 | −14 |
| Q4 2025 | 96 | -1 | 34.58M | $7.37B | — | −1 |
| Q3 2025 | 15 | 0 | 10.69M | $2.13B | +1 | −1 |
| Q2 2025 | 12 | -2 | 9.16M | $1.58B | — | −2 |
| Q1 2025 | 12 | +1 | 5.48M | $853.40M | +1 | — |
| Q4 2024 | 11 | -2 | 5.30M | $729.95M | — | −2 |
| Q3 2024 | 12 | +1 | 6.24M | $930.97M | +2 | −1 |
| Q2 2024 | 11 | — | 7.02M | $958.03M | — | — |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | T. Rowe Price ✦ | 2.12M | +18.9% | $316.71M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 2 | Wellington Management ✦ | 1.26M | -51.7% | $188.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Wellington Management ✦ | 1.26M | -51.7% | $188.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Wellington Management ✦ | 1.26M | -51.7% | $188.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.26M | -51.7% | $188.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.26M | -51.7% | $188.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.26M | -51.7% | $188.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 8 | Wellington Management ✦ | 1.26M | -51.7% | $188.35M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | Citadel Advisors ✦ | 663.92K | +23.5% | $99.13M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 663.92K | +23.5% | $99.13M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 11 | Millennium Management ✦ | 501.69K | +6.0% | $74.91M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 12 | Point72 Asset Management ✦ | 495.55K | Nuevo | $73.99M | 0.3% | New | 1 | SEC ↗ |
| 13 | Adage Capital Partners ✦ | 486.96K | -40.6% | $72.71M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 14 | Duquesne Family Office ✦ | 265.04K | Nuevo | $39.57M | 1.4% | New | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 221.07K | +629.9% | $33.01M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 16 | D. E. Shaw & Co. ✦ | 90.38K | -67.9% | $13.49M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | D. E. Shaw & Co. ✦ | 90.38K | -67.9% | $13.49M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Geode Capital Management ✦ (pasivo) | 56.45K | -2.3% | $8.43M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Two Sigma Investments ✦ | 50.09K | -80.4% | $7.48M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 20 | Baillie Gifford ✦ | 21.40K | -69.9% | $3.20M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 21 | Baillie Gifford ✦ | 21.40K | -69.9% | $3.20M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 22 | Baillie Gifford ✦ | 21.40K | -69.9% | $3.20M | 0.0% | ▼ Trim | 2 | SEC ↗ |
«Su ponderación» = la participación de la posición en el valor de renta variable 13F declarado por ese gestor — la medida de convicción. ✦ = gestor seleccionado.
Nuevos compradores
| Point72 Asset Management | $73.99M | 0.3% |
| Duquesne Family Office | $39.57M | 1.4% |
Posición cerrada
| Soros Fund Management | $13.64M | era 0.4% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 8 tenedores, 7.94M acciones, $34.76M declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué otros valores suelen tener también los tenedores rastreados de este activo — recuentos de cotenencia, no relaciones fundamentales.
Compras en mercado abierto (P)
Director · 1.10K acc. @ 245.85 · $270,435
Director · 900 acc. @ 246.91 · $222,219
Ventas en mercado abierto (S)
Sin ventas en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología